PriceTargets.com logo

RxSight - RXST Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $59.00
  • Forecasted Upside: 75.28%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$33.66 As of 12/20/2024 06:31 PM ET
▼ -4.53 (-11.86%)

This chart shows the closing price for RXST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New RxSight Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RXST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RXST

Analyst Price Target is $59.00
▲ +75.28% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for RxSight in the last 3 months. The average price target is $59.00, with a high forecast of $73.00 and a low forecast of $40.00. The average price target represents a 75.28% upside from the last price of $33.66.

This chart shows the closing price for RXST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 polled investment analysts is to moderate buy stock in RxSight. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/20/2024Stifel NicolausDowngradeBuy ➝ Hold$65.00 ➝ $40.00
12/11/2024Wells Fargo & CompanyReiterated RatingOverweight ➝ Equal Weight$56.00 ➝ $42.00
12/6/2024UBS GroupInitiated CoverageBuy$52.00
10/29/2024Jefferies Financial GroupInitiated CoverageBuy$72.00
9/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
8/20/2024Needham & Company LLCBoost TargetBuy ➝ Buy$54.00 ➝ $66.00
8/6/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$68.00 ➝ $54.00
8/6/2024Needham & Company LLCLower TargetBuy ➝ Buy$75.00 ➝ $54.00
8/6/2024Stifel NicolausLower TargetBuy ➝ Buy$70.00 ➝ $65.00
8/6/2024OppenheimerLower TargetOutperform ➝ Outperform$72.00 ➝ $65.00
7/15/2024BTIG ResearchBoost TargetBuy ➝ Buy$72.00 ➝ $73.00
7/10/2024Stifel NicolausLower TargetBuy ➝ Buy$75.00 ➝ $70.00
5/7/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$61.00 ➝ $68.00
5/7/2024OppenheimerBoost TargetOutperform ➝ Outperform$61.00 ➝ $72.00
5/7/2024Needham & Company LLCBoost TargetBuy ➝ Buy$64.00 ➝ $75.00
5/7/2024BTIG ResearchBoost TargetBuy ➝ Buy$61.00 ➝ $72.00
5/6/2024Stifel NicolausBoost TargetBuy ➝ Buy$64.00 ➝ $68.00
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$64.00
2/29/2024Stifel NicolausBoost TargetBuy ➝ Buy$54.00 ➝ $64.00
2/29/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$40.00 ➝ $62.00
2/29/2024OppenheimerBoost TargetOutperform ➝ Outperform$54.00 ➝ $61.00
2/29/2024Needham & Company LLCBoost TargetBuy ➝ Buy$53.00 ➝ $64.00
2/12/2024Stifel NicolausBoost TargetBuy ➝ Buy$45.00 ➝ $54.00
1/29/2024OppenheimerBoost TargetOutperform ➝ Outperform$50.00 ➝ $54.00
1/16/2024OppenheimerBoost TargetOutperform ➝ Outperform$46.00 ➝ $50.00
1/8/2024OppenheimerBoost TargetOutperform ➝ Outperform$38.00 ➝ $46.00
1/8/2024Needham & Company LLCBoost TargetBuy ➝ Buy$35.00 ➝ $41.00
12/13/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$31.00 ➝ $42.00
12/12/2023Stifel NicolausInitiated CoverageBuy$40.00
12/4/2023Morgan StanleyInitiated CoverageOverweight$36.00
11/10/2023Needham & Company LLCLower TargetBuy ➝ Buy$36.00 ➝ $30.00
8/8/2023OppenheimerBoost TargetOutperform ➝ Outperform$29.00 ➝ $34.00
8/8/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$34.00
7/17/2023BTIG ResearchBoost Target$29.00 ➝ $36.00
7/12/2023Needham & Company LLCBoost Target$27.00 ➝ $34.00
7/7/2023Bank of AmericaBoost Target$24.00 ➝ $32.00
6/5/2023BTIG ResearchBoost Target$25.00 ➝ $29.00
6/5/2023Wells Fargo & CompanyBoost Target$17.00 ➝ $27.00
4/19/2023Needham & Company LLCReiterated RatingBuy$22.00
4/12/2023OppenheimerInitiated CoverageOutperform$23.00
3/7/2023JPMorgan Chase & Co.Lower TargetOverweight$22.00 ➝ $20.00
3/3/2023Needham & Company LLCReiterated RatingBuy$22.00
2/7/2023Needham & Company LLCReiterated RatingBuy$22.00
12/12/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$20.00 ➝ $14.00
10/11/2022Bank of AmericaInitiated CoverageBuy ➝ Buy
8/9/2022Needham & Company LLCBoost TargetBuy$19.00 ➝ $22.00
4/8/2022Needham & Company LLCInitiated CoverageBuy$18.00
11/14/2021Leerink PartnersReiterated RatingBuy$20.00
10/22/2021Leerink PartnersReiterated RatingOutperform
8/24/2021JPMorgan Chase & Co.Initiated CoverageOverweight$16.00
8/24/2021Leerink PartnersInitiated CoverageOutperform$20.00
8/24/2021Wells Fargo & CompanyInitiated CoverageOverweight$20.00
8/24/2021BTIG ResearchInitiated CoverageBuy$28.00
8/24/2021Bank of AmericaInitiated CoverageBuy$17.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 9 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 12 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 13 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 14 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 16 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 18 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 26 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 26 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

RxSight logo
RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Read More

Today's Range

Now: $33.66
Low: $33.03
High: $36.20

50 Day Range

MA: $45.75
Low: $33.66
High: $54.73

52 Week Range

Now: $33.66
Low: $33.03
High: $66.54

Volume

2,255,349 shs

Average Volume

517,164 shs

Market Capitalization

$1.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of RxSight?

The following equities research analysts have issued research reports on RxSight in the last twelve months: BTIG Research, Jefferies Financial Group Inc., JPMorgan Chase & Co., Needham & Company LLC, Oppenheimer Holdings Inc., Stifel Nicolaus, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for RXST.

What is the current price target for RxSight?

0 Wall Street analysts have set twelve-month price targets for RxSight in the last year. Their average twelve-month price target is $59.00, suggesting a possible upside of 75.3%. BTIG Research has the highest price target set, predicting RXST will reach $73.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $40.00 for RxSight in the next year.
View the latest price targets for RXST.

What is the current consensus analyst rating for RxSight?

RxSight currently has 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RXST.

What other companies compete with RxSight?

Other companies that are similar to RxSight include Inspire Medical Systems, PROCEPT BioRobotics, Axonics, NovoCure and Envista. Learn More about companies similar to RxSight.

How do I contact RxSight's investor relations team?

The company's listed phone number is 949-521-7830 and its investor relations email address is [email protected]. The official website for RxSight is www.rxsight.com. Learn More about contacing RxSight investor relations.